Skip to main content
. 2016 May 26;7(27):41857–41869. doi: 10.18632/oncotarget.9621

Figure 4. Combination of dalantercept with sunitinib slows tumor growth and further reduces tumor blood flow in sunitinib resistant tumors.

Figure 4

A. A498 tumor-bearing mice were treated with sunitinib (40 mg/kg) until the tumors showed a 2 mm increase in long axis. After a 2 day drug holiday, animals were given vehicle (black line), sunitinib at (40 mg/kg, green line), dalantercept (10 mg/kg, brown line) or the combination of both drugs (blue line). Average tumor volume normalized to the initial average tumor volume for each group is shown. B. tumor perfusion was evaluated by ASL MRI on day 40 after the treatment change and average tumor perfusion is plotted in the graph. Su switched to the combination of Su + Dal vs Su continuous; * P=0.047. Su switched to Dal vs Su continuous; § P=0.006.